×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
The Honorable Tanya F. Otsuka
NCUA (.gov)
Tanya F. Otsuka was nominated by the President to serve on the NCUA Board on September 21, 2023. The U.S. Senate unanimously confirmed her by voice vote on...
3 weeks ago
Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic
STAT
The FDA has cleared Otsuka Pharmaceutical's Rejoyn, the smartphone-based treatment for major depressive disorder symptoms.
1 month ago
Otsuka Holdings Co., Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Simply Wall St
A week ago, Otsuka Holdings Co., Ltd. ( TSE:4578 ) came out with a strong set of first-quarter numbers that could...
3 days ago
Brown Applauds Tanya Otsuka's Confirmation to the NCUA Board
Senator Sherrod Brown (.gov)
Tanya Otsuka's confirmation to the National Credit Union Administration (NCUA) board. Otsuka previously worked for Chair Brown as Senior Counsel...
4 months ago
FDA clears Otsuka, Click's prescription app for depression
Fierce Biotech
Rejoyn aims to further reduce MDD symptoms by complementing standard-of-care drug regimens, with a six-week digital treatment schedule that...
1 month ago
Pharmavite, a U.S. subsidiary of Otsuka Pharmaceutical, acquires Bonafide Health, a provider of women's health ...
www.otsuka.co.jp
Through the acquisition of Bonafide Health, Pharmavite will expand its existing portfolio in the women's health field, comprised of Uqora, a...
5 months ago
Otsuka Drug Candidate Fails Phase III Alzheimer’s Agitation Study
BioSpace
AVP-786 was unable to significantly reduce total scores in the Cohen-Mansfield Agitation Inventory versus placebo, Otsuka Pharmaceuticals...
2 months ago
Senate confirms Otsuka to serve on NCUA board
Credit Union National Association | CUNA
The Senate voted to confirm Tanya Otsuka to serve on the NCUA board Wednesday.
4 months ago
Otsuka and Lundbeck's schizophrenia treatment gains EC approval
Pharmaceutical Technology
The EC has approved Otsuka and H Lundbeck's Abilify Maintena 720mg/960mg (aripiprazole) for the maintenance treatment of schizophrenia.
1 month ago
Otsuka, Click Therapeutics get FDA clearance for prescription digital therapeutic
MobiHealthNews
The new smartphone app, Rejoyn, will deliver treatment to patients taking antidepressant medication aimed at enhancing cognitive control of...
1 month ago